为评估口服乳三肽VPP(Val-Pro-Pro)和IPP(Ile-Pro-Pro)对血压的影响,基于综合性Meta分析选择了包含在21个研究中的27项临床实验、2142个高血压前期或高血压患者。由于存在异质性,采用随机影响模式进行分析。结果表明:Meta分析中未发现发表偏倚,收缩压(systolicbloodpressure,SBP)降低了1.78mmHg(95%可信区间为一2.47~一1.08,P〈0.001),舒张压(diastolicbloodpressure,DBP)降低了0.67mmHg(95%可信区间为一1.11~一0.23,P〈0.001)。亚组分析结果表明:亚洲人群SBP为一6.56mmHg、DBP为一3.01mmHg,2008年前的研究对象SBP为一6.57mmHg、DBP为一3.08mmHg,口服乳三肽剂量〈5mg/d的患者SBP为一5.20mmHg、DBP为一2.05mmHg,以及诊所偶测SBP(--2.74mmHg)与DBP(一1.18mmHg)和家庭自测SBP(--7.61mmHg)与DBP(--4.83mmHg)都显著下降,而相应的比较对象则没有。因此,包含乳三肽VPP~IPP的功能性食品对高血压前期或轻度高血压患者是有效的,特别是在低剂量食用时对亚洲人群的诊所偶测血压和家庭自测血压有明显效果。
A comprehensive meta-analysis was conducted to evaluate the effect of lactotripeptides (LTPs) Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) on blood pressure (BP) after oral administration. Twenty one randomized, placebo-controlled studies with 27 trials consisting of 2 142 prehypertensive or hypertensive individuals were identified through a defined search strategy, and due to heterogeneity among studies the random effect model was used for the analysis. The pool effect was a reduction of --1.78 mmHg [95% confidence interval (CI): --2.47 to --1.08, P 〈 0.001] for systolic blood pressure (SBP) and --0.67 mmHg (95% CI: --1.11 to --0.23, P 〈 0.001) for diastolic blood pressure (DBP), and no publication bias was present. Subgroup analyses showed that the intake of LTPs resulted in significant decreases in BP in Asians (SBP: --6.56 mmHg; DBP: --3.01 mmHg), in subjects from publications before 2008 (SBP: --6.57 mmHg, DBP: --3.08 mmHg) and participants with a dose of less than 5 mg/d (SBP: --5.20 mmHg; DBP: --2.05 mmHg), and in office SBP (--2.74 mmHg) and DBP (-- 1.18 mmHg) and home SBP (--7.61 mmHg) and DBP (--4.83 mmHg), whereas no significant effects were observed in their respective counterparts. These results suggest that functional foods containing LTPs may be useful as part of dietary intervention of pre- or mild hypertension.